NDLI: Guidelines for the use of extended-release nevirapine in HIV-infected patients.

Please wait, while we are loading the content...

The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia.

Linagliptin for the treatment of type 2 diabetes.

Effect of 2-year treatment with low-dose rosuvastatin on intima-media thickness in hypercholesterolemic subjects with asymptomatic carotid artery disease.

A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease.

Pharmacotherapy of chronic kidney disease and mineral bone disorder.

Olanzapine-fluoxetine combination for the treatment of bipolar depression.

Chronic urticaria: a comparison of management guidelines.

Guidelines for the use of extended-release nevirapine in HIV-infected patients.

Statins as potential treatment for cholesterol gallstones: an attempt to understand the underlying mechanism of actions.

Managing the combination of nonalcoholic fatty liver disease and metabolic syndrome.

Prevention and management of transplant-associated diabetes.

Mometasone furoate dry powder inhaler for the treatment of asthma.

Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma.

Telmisartan: just an antihypertensive agent? A literature review.

Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia.

Year: 2011 Volume: 12 Issue: 16

Year: 2011 Volume: 12 Issue: 15

Year: 2011 Volume: 12 Issue: 14

Year: 2011 Volume: 12 Issue: 13

Year: 2011 Volume: 12 Issue: 12

Year: 2011 Volume: 12 Issue: 11

Year: 2011 Volume: 12 Issue: 10

Year: 2011 Volume: 12 Issue: 9

Year: 2011 Volume: 12 Issue: 8

Year: 2011 Volume: 12 Issue: 7

Year: 2011 Volume: 12 Issue: 6

Year: 2011 Volume: 12 Issue: 5

Year: 2011 Volume: 12 Issue: 4

Year: 2011 Volume: 12 Issue: 3

Year: 2011 Volume: 12 Issue: 2

Year: 2011 Volume: 12 Issue: 1

Year: 2010 Volume: 11

Year: 2009 Volume: 10

Year: 2008 Volume: 9

Year: 2006 Volume: 7

Year: 2004 Volume: 5

Guidelines for the use of extended-release nevirapine in HIV-infected patients.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Heil, Emily L. Corbett, Amanda H.
Description	Country affiliation: United States Author Affiliation: Heil EL ( University of Maryland Medical Centre, 29 South Greene Street, Pharmacy Services, Suite 400, Baltimore, MD 21201, USA.)
Abstract	INTRODUCTION: Nevirapine (NVP) was the first non-nucleoside reverse transcriptase inhibitor (NNRTI) approved for the treatment of HIV infection and quickly became one of the most extensively used antiretrovirals (ARVs) worldwide. A new extended-formulation of the drug has now been FDA approved for once-daily use. AREAS COVERED: Two recent, randomized and controlled clinical trials have established the clinical noninferiority of a new, extended-release formulation of NVP (NVP XR), in both treatment-naive and treatment-experienced patients. VERxVE demonstrated the noninferiority of NVP XR in treatment-naive patients. Treatment-experienced patients already stable on the NVP immediate-release formulation (NVP IR) were safely transitioned directly to NVP XR in the TRANxITION study. EXPERT OPINION: The advantage of the extended release formulation of NVP is that it permits once-daily dosing, while demonstrating safety and efficacy results that are noninferior to that of the twice-daily formulation. It is expected that patients who are on NVP IR at present will consider switching to NVP XR to achieve regimen simplification by reducing their daily dosing and pill burden. In addition, treatment-naive patients who are considering starting on an NVP-based ARV regimen will probably transition to the extended-release formulation once they have successfully initiated NVP therapy according to current guidelines.
File Format	HTM / HTML
ISSN	14656566
Issue Number	17
Volume Number	12
e-ISSN	17447666
Journal	Expert Opinion on Pharmacotherapy
Language	English
Publisher	Taylor & Francis
Publisher Date	2011-12-01
Publisher Place	Great Britain (UK)
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Pharmacology Anti-hiv Agents Administration & Dosage Hiv Infections Drug Therapy Nevirapine Reverse Transcriptase Inhibitors Pharmacokinetics Cd4 Lymphocyte Count Delayed-action Preparations Immunology Metabolism Humans Journal Article Review
Content Type	Text
Resource Type	Article
Subject	Pharmacology Pharmacology (medical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Stavudine extended release (once-daily, Bristol-Myers Squibb) for the treatment of HIV/AIDS.

Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients.

Effect of efavirenz versus nevirapine in antiretroviral-naive individuals in the HIV-CAUSAL Collaboration Cohort.

Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.

Impact of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics in HIV-infected patients.

Antiretroviral therapy for HIV-infected children

Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals.

Nevirapine once daily: pharmacology, metabolic profile and efficacy data of the new extended-release formulation.

A randomized, open-label study of a nucleoside analogue reverse transcriptase inhibitor-sparing regimen in antiretroviral-naive HIV-infected patients.

Guidelines for the use of extended-release nevirapine in HIV-infected patients.

Similar Documents

Stavudine extended release (once-daily, Bristol-Myers Squibb) for the treatment of HIV/AIDS.

Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients.

Effect of efavirenz versus nevirapine in antiretroviral-naive individuals in the HIV-CAUSAL Collaboration Cohort.

Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.

Impact of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics in HIV-infected patients.

Antiretroviral therapy for HIV-infected children

Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals.

Nevirapine once daily: pharmacology, metabolic profile and efficacy data of the new extended-release formulation.

A randomized, open-label study of a nucleoside analogue reverse transcriptase inhibitor-sparing regimen in antiretroviral-naive HIV-infected patients.

Guidelines for the use of extended-release nevirapine in HIV-infected patients.